AZ-MANGATA-NETWORKS
16.9.2020 18:02:09 CEST | Business Wire | Press release
Mangata Networks announced today that it has been selected as a member of the 5G Open Innovation Lab, a global ecosystem of developers, start-ups, enterprises, academia and government institutions, focused on helping start-ups utilize 5G to develop new capabilities, use cases and market categories. Mangata Networks will work closely with the Lab’s founding partners including Intel, T-Mobile and other partners to further develop its 5G over satellite network solution. MangataEdgeTM will be a bit more than a satellite terminal integrating microEdge cloud computing with 5G radio access networking capability.
Brian Holz, CEO of Mangata Networks said “the 5G Open Innovation Lab is a fantastic opportunity for our team. We look forward to working with TMobile, Intel and their partners to further develop and define our core terrestrial networking product, ensuring seamless integration into 5G networks at affordable costs. MangataEdgeTM will allow operators to bring the cloud directly to businesses, communities and individuals, enabling them to effectively do their bit.”
Unique to the Lab’s approach is its focus on unifying an independent ecosystem by bringing together technology, financial and community partners and forward-thinking customers from industries such as media and entertainment, transportation, oil and gas, manufacturing, and retail.
Integrating satellite over 5G in a seamless, cost-effective manner enables information exchange and service delivery by communities and individuals not well connected today. The 5G Open Innovation Lab will give Mangata Networks access to leading edge technology, partnerships, resources, and environment to ensure their 5G product is a success.
“The 5G OI Lab is an extraordinary opportunity for developers to work directly with technology and business leaders to design and bring to life their vision and dreams for new 5G applications,” said Jim Brisimitzis, managing partner of the 5G OI Lab. “This is not just any startup program. We are building a true partner ecosystem that will bring knowledge, resources and capital together to change the world in profound ways.”
About the 5G Open Innovation Lab
The 5G Open Innovation Lab (5G OI Lab) is a global ecosystem of developers, start-ups, enterprises, academia and government institutions working together to fuel the development of new 5G capabilities and market categories that will transform the way we work, live and play both now and in the future. The Lab provides developers at all stages unparalleled access to open platforms, enterprises and markets needed to create, test and deploy new use cases and innovations for 5G. To learn more about the Lab and its portfolio of companies, please visit https://www.5GOILab.com/ or follow us on Twitter at @5GOILab.
About Mangata Networks
Mangata Networks, a joint venture with Intellectual Ventures Invention Science Fund, is a satellite enabled telecommunications company seeking to transform human potential into action. Our solution: creating a seamless global network to support businesses, communities, and individuals to do their bit. Our single core network allows rapid scaling of data connectivity across geographies. With a global footprint, our technology can be mobilized by businesses to reach their highest potential anywhere at an affordable price. To learn more about Mangata Networks, please visit https://www.mangatanetworks.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005591/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom